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1. Introduction 
Antiphospholipid syndrome (APS) is the most common acquired thrombophilia in 
pregnant women. This syndrome is characterized by vascular thrombosis and/or 
pregnancy morbidity in association with the presence of circulating antiphospholipid 
antibodies (aPL). The APS may occur alone (primary APS), or in association with an 
underlying autoimmune connective tissue disorder (secondary APS).(1)(2) The APS 
diagnosis requires at least one of the clinical criteria and one of the laboratory criteria 
described in Table 1. 
APS has been largely related to recurrent miscarriages (RM) and several pregnancy 
complications as pre-eclampsia, but their association with implantation failure (IF) after in 
vitro fertilization (IVF) is still a matter of debate. IF, defined as a failure in conceive after IVF 
treatment, is considered a cause of recurrent gestational failure (RGF), a current concept that 
includes both RM and IF. There is no consensus about the number of IVF failures cycles or 
the number of embryos transferred needed for the diagnostics of IF, but the majority of the 
clinicians consider 3 fresh IVF attempts’ failures for the diagnosis.(3)  
Assisted Reproduction Techniques (ART) development has tremendously increased the 
pregnancy rates (around 50%) by improvements in culture conditions, embryo selection and 
technical advances, but implantation is consider to be an important limiting factor in this 
field. Numerous anatomical, endocrine, immunological, thrombophilic and genetic 
alterations have been described as risk factors in IF. (4)  
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Clinical criteria 
Vascular thrombosis  
≥1 clinical episodes of arterial, venous, or small vessel 
thrombosis, in any tissue being confirmed by appropriate 
imaging studies or histopathology without evidence of 
inflammation in the vessel. 
Pregnancy morbidity 
≥1 unexplained deaths of a morphologically normal foetus at or 
beyond the 10th week of gestation, with normal foetal 
morphology documented. 
≥1 premature births of a morphologically normal neonate 
before the 34th week of gestation due to eclampsia and severe 
preeclampsia, or to recognized features of placental 
insufficiency. 
≥3 unexplained consecutive spontaneous abortions before the 
10th week of gestation, with maternal anatomic or hormonal 
abnormalities, and paternal and maternal chromosomal causes 
excluded. 
Laboratory criteria  
Lupus anticoagulant  
Present in plasma, on ≥2 occasions at least 12 weeks apart, 
detected according to the guidelines of the International Society 
on Thrombosis and Haemostasis (Scientific Subcommittee on 
LAs/phospholipid-dependent antibodies)  
Anticardiolipin antibody 
of IgG and/or IgM isotype 
Present in serum or plasma at medium or high titre (>40 GPL 
or MPL, or >99th percentile), on >2 occasions, at least 12 weeks 
apart, measured by a standardized enzyme-linked 
immunosorbent assay (ELISA)  
Anti-β2GPI antibody of 
IgG and/or IgM isotype  
Present in serum or plasma (titre >99th percentile), ≥2 
occasions, at least 12 weeks apart, measured by a standardized 
ELISA, according to recommended procedures  
Table 1. Clinical and Laboratory criteria for the diagnosis of the APS. Adapted from 
Miyakis, S. et al. (2006). Abbreviations: β2GPI, β2 glycoprotein I; ELISA, enzyme-linked 
immunosorbent assay; GPL, IgG phospholipid units; GPM, IgM phospholipid units. 
2. Implantation process 
Embryo implantation and successful establishment of pregnancy require delicate 
interactions between the blastocyst and the maternal uterine cells. From the embryo phase, 
the trophectoderm and the throphoblast establish contact with the specialized maternal 
tissue, the uterine endometrium. Classically, implantation process has been divided into 
three phases: apposition, adhesion and invasion of a developmentally competent embryo in 
the receptive endometrium. Implantation begins with attachment of the blastocyst 
trophoblast (derived from the trophectoderm) at the embryonic pole through the outer 
epithelial uterine lining (day 6 from the fertilization). The site of implantation is marked on 
the surface by a coagulation plug left where the blastocyst has entered the uterine wall (day 
12 from the fertilization). This phenomenon triggers changes in both the trophoblast and the 
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connective tissue (stroma) beneath the uterine epithelium. Some trophoblast cells fuse to 
make a syncytium called the syncytiotrophoblast that releases proteolytic enzymes that 
allow passage of the blastocyst into the endometrial wall first, then into the stroma (carrying 
the whole conceptus with it). 
During this migration, the trophoblast cells destroy the wall of the maternal uterine spiral 
arteries, converting them from muscular vessels into flaccid sinusoidal sacs. This vascular 
transformation is important to ensure an adequate blood supply to the feto-placental unit 
and the beginning of the histiotrophic nutrition. (5) 
A change in endometrial gene expression is necessary to allow the embryo implantation. In 
fact, already in the late luteal phase, physiological changes occur in the endometrium to 
allow blastocyst implantation.  Uterine cells changes their phenotype during the menstrual 
cycle and these critical events during this so called "window of implantation or receptivity" 
results  in the presence of the embryo, in a decidual reaction, leading to programs of gene 
expression particular to pregnancy. Failure to properly begin these critical events results in 
early implantation failure. 
3. Disorders of implantation 
Adequate implantation is a limiting factor in human reproduction. The study of the possible 
causes responsible of this failure is technically difficult in the daily clinical routine. As 
previously described, implantation is the result of the remarkable synchronization between 
the development of the embryo and the differentiation of the endometrium. 
Uterine pathologies like adhesions, septa, intrauterine polyps, hydrosalpinx, endometriosis 
and other disorders might impair implantation. Several studies suggest that reparatory 
surgery improves the conception rate. However, there is still an ongoing debate on the 
benefits of surgery in infertile patients. (6-10) 
During the last few years several authors have reported different gene networks important 
for the endometrium receptivity that controls the expression of key transcription factors (e.g. 
HOXA10, STAT3, p53) (11-15), growth factors and cytokines [e.g. HB-EGF, leukaemia-
inhibiting factor (LIF), prokineticin 1] (16-18)( and cell adhesion molecules and their ligands 
(e.g. avb3 integrin, trophinin, L-selectin ligand) (19-21), all of which are essential for 
coordinated cross-talk with the implanting embryo. (22)  Altmae et al. demonstrated that 
women with IF show a somewhat different endometrial gene profile during the window of 
implantation, (23) which is thought to contribute to the lower implantation rates seen in these 
patients. In particular, investigations focusing on endometrium of IF patients showed 
changes in known implantation markers, such as integrins, as well as leukaemia inhibitory 
factor (LIF) and interleukin-1 (IL-1). (24) 
Natural killer (NK) cells have been recently identified among the relevant immunological 
factors for reproductive success (25). Of note, uterine natural killer (NK) cells 
(CD56brightCD16-) represent the dominant type of immune cells in the decidua (around 70% 
of feto-maternal interface lymphocytes), and it has been suggested that they contribute to 
the normal trophoblast invasion control and angiogenesis process. An increased number 
and cytotoxic activity of blood NK cells (CD56dimCD16+) and their presence in the 
endometrium of pregnant women has been related to pregnancy loss. Circulating NK cell 
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expansion has been also associated to the presence of antiphospholipid antibodies in women 
with RM and has been ascribed to antiphospholipid-mediated specific reactions (26). 
4. Thrombophilias and IF 
Acquired and inherited thrombophilias are associated with adverse pregnancy outcome. 
Thrombophilias has been largely related to RM and several pregnancy complications as pre-
eclampsia, late foetal dead, foetal grow restriction and placenta abruption. 
With respect to recurrent IF, although the medical literature is not as substantive as that of the 
recurrent pregnancy loss field, the data again suggest that thrombophilia is associated with 
repeated IF. Several authors have reported a significantly higher prevalence of thrombophilias 
in women with four or more failed IVF cycles when compared with spontaneous 
conceptions.(27-30) Due to the limitations on the knowledge of the implantation process, the 
mechanisms underlying these associations still remain unclear. Thrombophilias would affect 
on the ability of the endometrium to develop adequately, communicate effectively with the 
embryo, or potentially disrupt the early interactions with the maternal circulation.  
The inherited thrombophilic conditions can be classified into five broad groups. Each 
inherited thrombophilia has variable frequency depending on race and ethnicity. In 
Caucasians, the most common are showed in Table 2. (31,32) 
 
Trombophilia Incident VTE (%) Recurrent VTE (%) Normal population 
Factor V Leiden 20 40–50 3–7 
Prothrombin G20210A 
mutation 
3–8 15–20 1–3 
Antithrombin 
deficiency 
1–2 2–5 0.02–0.04 
Protein C deficiency 2–5 5–10 0.2–0.5 
Protein S deficiency 1–3 5–10 0.1–1 
Table 2. Prevalence of genetic defects among Caucasians 
APS has been largely related to recurrent miscarriages (RM) and several pregnancy 
complications such as pre-eclampsia, prematurity, abruption placentae and the HELLP 
syndrome (haemolysis, elevated liver enzymes, low platelets count), and others.  It is 
considered the most frequently acquired risk factor for thrombophilia and the main risk of 
pregnancy loss. However, their association with IF after IVF is still a matter of debate. (33,34) 
In vitro and in vivo mice models have demonstrated that antiphospholipid antibodies (aPL) 
are able to increase thrombus formation in venous and arteries.  (35,36) 
Antiphospholipid syndrome antibodies (aPL), anticardiolipin (aCL), anti-β2 glycoprotein I 
(β2GPI) and lupus anticoagulant (LA), are believed to have a pathogenic role. Several 
authors have reported changes in endothelial adhesion molecules expression as well as in 
nitric oxide and tissue factor expression in the presence of aPL. These changes could induce 
coagulation cascade activation but the cells and the exact mechanism involved in clot 
formation still remains to be elucidated. 
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β2GPI-dependent aPL is considered the antibody subpopulation responsible for the 
thrombotic manifestations of APS. The expression of β2GPI on trophoblast cell membranes 
explains the placental tropism of anti-β2GPI antibodies and the possible role of these 
antibodies in pregnancy loss. Placental thrombosis, acute inflammation and complement 
activation have been described as possible responsible of foetal loss in APS patients. 
In vitro studies showed that aPL might induce a procoagulant status at the placental level 
through several mechanisms including the ability of the aPL antibodies (specifically, 
anti-β2GPI antibodies) to disrupt the anticoagulant annexin A5 shield on trophoblast but 
histopathological studies have not demonstrated thrombosis findings in most APS women 
placentas. (37) 
An adequate balance between pro-inflammatory and anti-inflammatory arms of the 
immune response is necessary for a successful pregnancy outcome (38). Complement 
activation could be involved in APS foetal loss pathogenesis because of the demonstration 
that the protective effect of heparin in the mouse model is linked to the anticomplement, 
rather than to the anticoagulant, activity. (39) 
We still do not know the precise mechanisms responsible of the high diversity of clinical 
manifestations in APS patients. Several authors have reported studies in vitro and in vivo 
trying to explain pregnancy loss and vascular implications of the syndrome, but in IF cases 
the potential pathogenic mechanisms are less known. β2GPI-dependent antibodies bind to 
human trophoblast and could affect several cell functions needed for the correct embryo 
implantation like proliferation and syncytium formation. These antibodies could decrease 
production of human chorionic gonadotrophin and others important factors for the invasion 
of the trophoblast. (40) In addition, expression of important factors for the implantation in the 
endometrium has been found in reduced quantities in women with aPL. Also, it has been 
shown that β2GPI-dependent aPL are able to react with human stromal decidual cells in 
vitro, inducing a proinflammatory phenotype. (41,42) 
A wide range of different antigenic specificities has been described in APS (Table 3), and 
could be determined when the clinical suspicion of obstetrical APS is strong and the 
classical anticardiolipin antibodies (aCL), anti- β2GPI and LA are all negative. 
5. Prevalence of antiphospholipid antibodies in recurrent gestational failure 
We consecutively studied 157 women that fulfilled diagnosis of RPL, of age range from 28 to 
41 (mean age, 36.86±3.93), from whom 60 presented with RM with a mean of 3.28±1.14 prior 
miscarriages; and 97 presented with IF, with a mean of 4.75±2.17 prior failed IVF. In the 
group of RM, 13.62% showed positive antiphospholipid antibodies (mostly low titre 
anti-β2GPI or/and aCL); only a 4.60% showed moderate to high titres of antiphospholipid 
antibodies and therefore fulfilled criteria of APS. In the group of IF, 18.80% of patients 
showed positive antiphospholipid antibodies (all of them low titre anti-β2GPI or/and aCL). 
A 97% of patients with antiphospholipid antibodies in our series had also expanded 
circulating NK cells (above 12%). The allele frequency prevalence of the mutations in the 
genes of factor V Leiden, the prothrombin G20210A, and the methylenetetrahydrofolate 
reductase (MTHFR C677T) in the general population in the European population represent 
approximately a 2.5%, 2.2%, and 35.3%, respectively. (43) We systematically studied all three 
mutations in our cohort of patients with RPL. We observed that in the group of RM, the  
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Reagin 
Anionic phospholipids 
Cardiolipin 
Phosphatidylserine 
Phosphatidic acid 
Phosfatidilinositol 
Neutral phospholipids 
Phosfatidilcoline 
Dipolar phospholipids 
Phosphatidyletanolamine 
Phospholipid-linking proteins 
β-2-glicoprotein I 
Prothrombin 
Annexin V 
Protein C 
Protein S 
High and low molecular weight kininogens 
Other 
Table 3. Different specificities of antiphospholipid antibodies 
10.8% was homozygous for MTHFR mutation and the 64.9% were carriers. In the group of 
IF, the 8.3% was homozygous for MTHFR mutation and the 55.6% were carriers. The 
frequencies of carriers of mutations of factor V Leiden were 3.12% in RM and 6.25% in IF, 
respectively; the frequencies of carriers of mutations of prothrombin were 3.12% in RM and 
0% in IF, respectively. No homozygous for both factors were observed in our series of 
patients. 
6. Clues in management of thrombophilia in recurrent pregnancy loss 
In addition to the risk of embryo and foetal losses, there is a low but actual risk of maternal 
morbidity due to coagulation disorders. The risk of pulmonary embolism and/or deep vein 
thrombosis increases during pregnancy and puerperium, and is further enhanced by the 
presence of acquired or inherited thrombophilias. (1) This thromboembolic complications 
remain as a main cause of maternal death during pregnancy, and its incidence is increasing. 
For the presence of antiphospholipid antibodies, the risk of pregnancy-related severe 
maternal thrombosis has been estimated by an odds ratio of 15.8 (95%CI 10.9–22.8). (44)  
Based on meta-analyses of randomized controlled studies, observational studies and clinical 
reports, the American College of Physicians has made the following recommendations: (45,46) 
1. For women with aPL and recurrent pregnancy loss, and no history of venous or arterial 
thrombosis, a prophylactic dose of unfractionated heparin combined with low-dose 
aspirin antepartum is recommended (Grade 1B).  This combination has been shown to 
be effective in reducing miscarriage rates in women with aPL and prior recurrent foetal 
loss. This treatment regimen is significantly more effective that others, such as 
corticosteroids either alone or with aspirin, and IV gammaglobulin. Two recent pilot 
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studies suggest that the combination of low molecular weight heparin (LMWH) and 
aspirin might be equivalent to unfractionated heparin and aspirin in preventing 
recurrent pregnancy loss. (47,48) Our protocol is based in the modified protocol proposed 
by Ray with combined low-dose aspirin and low-molecular weight heparin. (49) 
2. For women at high risk for pre-eclampsia, low-dose aspirin throughout pregnancy is 
recommended (Grade 1B). Treatment seems to be more effective if started early in 
pregnancy and at appropriate dose (75–100 mg once daily). An effect of anticoagulant 
therapy on the risk of preeclampsia is biologically plausible. However, the results of 
previous small sized studies are still controversial, and the presence of thrombophilia 
has not been considered in randomized trials on prevention. (1) 
3. For women with thrombophilia and previous late foetal loss, placental abruption 
and/or foetal growth retardation, the available data do not suffice to form the basis of a 
recommendable prophylactic protocol.  
From a clinical perspective, there is still controversial the decision of the adequate 
thromboprophylaxis protocol for preventing IF and RM in several thrombophilic alterations, 
such as factor V Leiden and/or prothrombin mutations’ carriers in otherwise asymptomatic 
women. In particular, MTHFR mutation has been shown to lack clinical significance alone. 
However, an argument to justify prophylaxis could be made that the recurrence risk of 
women with prior foetal loss, abruption, severe IUGR, or severe preeclampsia is high 
enough (5–30%). Although there are no randomized clinical trials to support such an 
approach, observational studies of low-dose aspirin, and LMWH have reported 
improvement in birth weight compared with untreated pregnancies. Such patients should 
be offered postpartum anticoagulation prophylaxis if they have an affected first-degree 
relative or thrombotic risk (e.g., caesarean delivery) (50) Finally, although low corticosteroid 
doses (<20 mg/day) are occasionally used, particularly in women unresponsive to the 
standard combination therapy (low‐dose aspirin and heparin), there is no evidence to 
support the routine use of corticosteroids. (2) 
7. Conclusions 
Multiple acquired and genetic thrombophilic conditions may interact or act in addition as 
causes of recurrent pregnancy loss. Antiphospholipid antibodies are a heterogeneous group 
of autoantibodies with varying affinity for different phospholipids and protein-
phospholipid complexes with direct pathogenic role resulting in lower blood flow and/or 
thrombosis at the maternal-foetal interface and final embryo/foetus loss, among other 
potential maternal complications. Our results in a cohort of patients with recurrent 
pregnancy loss suggest that aPL may have a similar role in IF patients as in RM patients. 
Quantification of these thrombosis risk factors in women with RPL will contribute to a 
better understanding of the interaction of genetic and acquired risk factors, and to better 
adjust in a more personalized approach the best management for a successful gestation. 
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